How to buy Brickell Biotech stock

Brickell Biotech, Inc is a biotechnology business based in the US. Brickell Biotech shares (BBI) are listed on the NASDAQ and all prices are listed in US Dollars. Brickell Biotech employs 13 staff and has a trailing 12-month revenue of around 0.00.

Brickell Biotech share price

Use our graph to track the performance of BBI stocks over time.

Brickell Biotech shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$0.47 - $2.61
50-day moving average	$1.06
200-day moving average	$0.96
Wall St. target price	$5.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-9.55

Buy Brickell Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Brickell Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Brickell Biotech, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Brickell Biotech financials

Revenue TTM	$1.8 million
Gross profit TTM	$-9,394,000
Return on assets TTM	-50.64%
Return on equity TTM	-120.51%
Profit margin	0%
Book value	$2.33
Market capitalisation	$68.2 million

TTM: trailing 12 months

Shorting Brickell Biotech shares

There are currently 4.5 million Brickell Biotech shares held short by investors – that's known as Brickell Biotech's "short interest". This figure is 1.3% down from 4.6 million last month.

There are a few different ways that this level of interest in shorting Brickell Biotech shares can be evaluated.

Brickell Biotech's "short interest ratio" (SIR)

Brickell Biotech's "short interest ratio" (SIR) is the quantity of Brickell Biotech shares currently shorted divided by the average quantity of Brickell Biotech shares traded daily (recently around 1.8 million). Brickell Biotech's SIR currently stands at 2.46. In other words for every 100,000 Brickell Biotech shares traded daily on the market, roughly 2460 shares are currently held short.

However Brickell Biotech's short interest can also be evaluated against the total number of Brickell Biotech shares, or, against the total number of tradable Brickell Biotech shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Brickell Biotech's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Brickell Biotech shares in existence, roughly 70 shares are currently held short) or 0.0694% of the tradable shares (for every 100,000 tradable Brickell Biotech shares, roughly 69 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Brickell Biotech.

Find out more about how you can short Brickell Biotech stock.

Brickell Biotech share dividends

We're not expecting Brickell Biotech to pay a dividend over the next 12 months.

Have Brickell Biotech's shares ever split?

Brickell Biotech's shares were split on a 1:7 basis on 2 September 2019. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brickell Biotech shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Brickell Biotech shares which in turn could have impacted Brickell Biotech's share price.

Brickell Biotech overview

Brickell Biotech, Inc. , a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado. .

Frequently asked questions

• What percentage of Brickell Biotech is owned by insiders or institutions?

  Currently 1.815% of Brickell Biotech shares are held by insiders and 12.301% by institutions.

• How many people work for Brickell Biotech?

  Latest data suggests 13 work at Brickell Biotech.

• When does the fiscal year end for Brickell Biotech?

  Brickell Biotech's fiscal year ends in December.

• Where is Brickell Biotech based?

  Brickell Biotech's address is: 5777 Central Avenue, Boulder, CO, United States, 80301

• What is Brickell Biotech's ISIN number?

  Brickell Biotech's international securities identification number is: US10802T1051

• What is Brickell Biotech's CUSIP number?

  Brickell Biotech's Committee on Uniform Securities Identification Procedures number is: 10802T105